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Abstract A synthetic N-myristoylated peptide corresponding to 
the amino-terminal domain of ADP-ribosylation factor 1 (ARF1) 
markedly increases, in a cell-free system using post-nuclear 
supernatant from PC12 cells, the biogenesis of constitutive 
secretory vesicles and immature secretory granules from the 
trans-Goigi network (TGN). The related N-myristoylated ARF4 
peptide only weakly stimulates, and the non-myristoylated ARF1 
and ARF4 peptides inhibit, the biogenesis of these secretory 
vesicles. In a modified cell-free system using TGN membranes, 
eoatomer-depleted cytosol supports the biogenesis of TGN- 
derived secretory vesicles to the same extent as control cytosol. 
These results suggest a role for ARF1, but not the COP I coat, in 
secretory vesicle biogenesis from the TGN, possibly via the 
activation of phospholipase D. 
[10,11], the biogenesis of both CSVs and ISGs, collectively 
referred to as TGN-derived secretory vesicles, is inhibited by 
brefeldin A. I f  one extrapolates from the observations on the 
formation of cis-Golgi-derived vesicles to the biogenesis of 
TGN-derived secretory vesicles, the inhibition by brefeldin 
A would be indicative of an involvement of ARF  in the latter 
process [12]. In the present study, we have examined a possi- 
ble role of ARF  in the biogenesis of TGN-derived secretory 
vesicles. In addition, we have addressed the related question 
of whether or not coatomer is required for the biogenesis of 
these vesicles. 
2. Materials and methods 
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1. Introduction 
Over the past few years, considerable progress has been 
made in understanding the molecular mechanisms that under- 
lie the biogenesis of vesicles mediating membrane traffic in the 
secretory pathways of eukaryotic ells [1,2]. In particular, the 
biogenesis of transport vesicles derived from the cis-Golgi of 
mammalian cells [2] has served as a conceptual paradigm for 
the study of vesicle biogenesis from other donor compart- 
ments. Two classes of cytosolic proteins have emerged as 
key components in the biogenesis of these vesicles, (i) the 
small GTP-binding protein ADP-ribosylation factor (ARF) 
and (ii) the coatomer complex forming the COP I coat [2]. 
ARF  binds to Golgi membranes in the GTP state via its 
amino-terminal myristate [3], and mediates the membrane re- 
cruitment of coatomer [4,5]. The GDP-GTP exchange on 
ARF  is regulated by a membrane-associated guanine nucleo- 
tide exchange factor that is inhibited by the drug brefeldin A 
[6,7] which blocks membrane recruitment of coatomer and 
vesicular transport [8]. 
We have previously reconstituted, in a cell-free system de- 
rived from the neuroendocrine cell line PC12, the biogenesis 
of constitutive secretory vesicles (CSVs) and immature secre- 
tory granules (ISGs) from the trans-Golgi network (TGN) [9]. 
Interestingly, in this cell-free system [10] and in intact cells 
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2.1. Peptides and antibodies 
All peptides were synthesised on a 25 grnol scale with an Abimed 
AMS 422 Multiple Peptide Synthesiser using a PyBOP activation and 
Fmoc/tBu/Boc protection scheme. For N-myristoylation, the Fmoc 
group on the N-terminal glycine was removed, and 25 I.tmol of the 
resin-attached peptide was myristoylated for twice 3 h with a 10-fold 
molar excess of myristoyl chloride in 450 p.l N,N-dimethylformamide 
and 50 Ixl 50% 4-methylmorpholine/N,N-dimethylformamide. The 
myristoylated peptides were cleaved from the resin (p-hydroxy- 
methyl-phenoxymethyl polystyrene), and deprotected, with 95% tri- 
fluoroacetic acid/5% water for 3 h, precipitated with ice-cold diethyl 
ether, dissolved in 70% acetonitrile/water, and lyophilized overnight. 
All peptides were analyzed and purified by reverse-phase HPLC, and 
their predicted composition verified by matrix-assisted laser desorp- 
tion ionization time of flight mass spectrometry, and amino acid ana- 
lysis. Peptides were stored at -20°C as 10 mM stocks; those with a 
free amino terminus were dissolved in dH20, while N-myristoylated 
peptides were dissolved in dimethyl sulphoxide (DMSO). Monoclonal 
antibody CM1A10 was a kind gift of Dr. Jim Rothman. 
2.2. Cell-free system using PNS 
Cell-free biogenesis of TGN-derived secretory vesicles using PNS 
from [3~S]sulphate-labelled PC12 cells was carried out for 60 min at 
37°C as described previously [9,13], with ARF peptides being added 
as indicated in the legend to Fig. 1. 
2.3. Modified cell-free system using TGN membranes supplemented 
with cytosol 
2.3.1. Preparation of TGN membranes. All the following manip- 
ulations were performed at 4°C. A [3~S]sulphate-labelled PNS (3 ml), 
prepared from six 15 cm dishes of PC12 cells as described previously 
[9,13], was layered over a 5 ml step of 0.8 M sucrose on top of a 5 ml 
cushion of 1.2 M sucrose in an 'Ultra-clear' tube for the Beckman 
SW40 rotor, all sucrose solutions being buffered with 10 mM HEPES- 
KOH to pH 7.2. Centrifugation was carried out at 25000 rpm 
(ll0000×gav) for 30 min in a Beckman SW40 rotor. The 0.8-1.2 
M sucrose interface was then collected using a 1 ml syringe and 22 
gauge needle. This interface, containing TGN membranes, typically 
had a volume of 500-600 I.tl, a sucrose concentration of 1.0 M, a total 
35S radioactivity of 2× 103 cpm/lil, and a protein concentration of 
1.6-1.7 mg/ml. For cell-free biogenesis of TGN-derived secretory ve- 
sicles, 80 I.tl aliquots of this membrane suspension, each corresponding 
to approximately one labelled 15 cm dish of PC12 cells, were used 
immediately. 
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Fig. 1. Effects on the cell-free biogenesis of TGN-derived secretory vesicles of non-myristoylated and N-myristoylated peptides corresponding to 
the amino-terminal domain of ARF1 and ARF4. Cell-free reactions using PNS were carried out in the presence of the indicated concentrations 
of either unmodified (A and B) or N-myristoylated (C and D) peptides corresponding to the amino-terminal 15 amino acid residues of ARF1 
(open circles) and ARF4 (closed circles). The unmodified peptides (A and B) were added from a 10 mM stock in dH20, while the N-myristoy- 
lated peptides (C and D) were added from a 10 mM stock in DMSO. Two control reactions received DMSO only, at an amount corresponding 
to the solvent present at the highest peptide concentration used (open triangles in C and D). The biogenesis of CSVs (hsPg, A and C) and 
ISGs (SglI, B and D) was determined as described in section 2. The budding efficiencies are expressed as a percentage of the control (no ARF 
peptide) and are the means of three independent experiments. Bars indicate the standard eviation. The variation for the two control reactions 
with DMSO was ,'~ 5% and is not shown for clarity. 
2.3.2. Preparation of control cytosol. A PNS was prepared from 
unlabelled PC12 cells following the previously published procedure 
[9,13] but made to be twice the standard concentration. This PNS 
was centrifuged at 4°C for 20 min at 45000 rpm (170 000 × g~v) in a 
Beckman TLS-55 rotor. For cytosol made from rat brain the same 
proceedure was followed except hat a 12500×gay supernatant de- 
rived from rat brain homogenate [14] was used instead of the PC12 
cell PNS. The typical protein concentration f the PC12 cell and rat 
brain cytosol was 6 mg/ml and 3 mg/ml, respectively. Cytosols were 
snap frozen in liquid nitrogen and stored at -80°C. 
2.3.3. Preparation of coatomer-depleted cytosol. The mouse 
monoclonal IgG CM1A10, raised against he native coatomer, was 
coupled to protein G-agarose as described [15]. The CM1A10 protein 
G-agarose was stored at 4°C as a 50% suspension i PBS with 0.5%0 
azide. Rat brain cytosol was immunodepleted of coatomer by sequen- 
tial incubations with CM1A10 protein G-agarose (100 Ixg/mg of cyto- 
solic protein) for 6 h, 6 h and 12 h at 40C with mixing. The extent of 
immunodepletion was assessed by immunoblot analysis of untreated 
and immunodepleted cytosol using a rabbit polyclonal antibody to the 
36 kDa subunit of the mammalian coatomer. Immunoblots were 
quantitated using laser-scanning densitometry. 
2.3.4. Cell-free reactions. 80 p.1 of [asS]sulphate-labelled TGN 
membranes were supplemented on ice with 50 ~tl of 10 mM 
HEPES-KOH pH 7.2, 200 Ixl homogenisation buffer [9,13], 800 lal 
of cytosol as indicated in the figure legends, 50 lal of 10 mM 
Mg(OAc)2 and then 50 lal of an ATP regenerating system [9,13]. In 
some experiments, the conditions were modified by use of an ATP 
depleting system [9,13] instead of the ATP regenerating system, or by 
the addition of GTI~/S, as indicated in the figure legends. The samples 
were mixed by inverting twice. Cell-free reactions were then carried 
out at 4°C and 370C for 60 min, and samples placed on ice thereafter. 
2.4. Analysis of cell-free biogenesis of TGN-derived secretory vesicles 
TGN-derived secretory vesicles were separated from the TGN by 
means of velocity-controlled centrifugation  linear, 0.3 M to 1.2 M, 
sucrose gradients as described previously [9,13]. In some experiments, 
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Fig. 2. The modified cell-free system. (A and B) Modified cell-free 
reactions using TGN membranes supplemented with PC12 cell cyto- 
sol to a final protein concentration of 2 mg/ml were performed as 
follows: 4°C in the presence of ATP and a regenerating system 
(4°C +ATP); 37°C in the presence of an ATP depleting system 
(37°C -ATP); 37°C in the presence of ATP and a regenerating sys- 
tem (37°C +ATP); 37°C in the presence of ATP, a regenerating sys- 
tem, and 20 IxM GTP'yS (37°C +ATP+GTPTS ). The biogenesis of 
CSVs (hsPg, A) and ISGs (SglI, B) was determined as described in 
section 2. The budding efficiencies are expressed as a percentage of
the control (37°C +ATP) and are the means of two independent ex- 
periments. Bars represent the deviation of the individual values 
from the mean. The mean budding efficiency for the control condi- 
tion was 22% for the hsPg and 28% for SglI. (C) Modified cell-free 
reactions were carried out using TGN membranes supplemented 
with PC12 cell cytosol to the indicated final protein concentrations. 
The biogenesis of CSVs (hsPg, closed circles) and ISGs (SglI, open 
circles) was determined and is expressed asbudding efficiency as de- 
scribed in section 2. 
TGN-derived secretory vesicles were further fractionated by equili- 
brium centrifugation [9,13] using a modified linear, 0.5 M to 1.6 M, 
sucrose gradient [16]. Aliquots of velocity and equilibrium sucrose 
gradient fractions were analysed by SDS-PAGE and fluorography 
[9,13]. To quantitate the cell-free biogenesis of CSVs and ISGs, the 
'budding efficiencies' were determined; these were defined, calculated 
and expressed asdescribed previously [17]. 
3. Results 
3,1. Effects on cell-free secretory vesicle biogenesis from the 
TGN of unmodified and N-myristoylated peptides 
corresponding to the amino-terminal domains of ARF1 
and A RF4 
To investigate a possible role of ARF in the biogenesis of 
TGN-derived secretory vesicles, we examined, in the cell-free 
system using PC12 cell PNS, the effects of synthetic peptides 
corresponding in sequence to the N-terminal 15 residues of 
ARF1 (GNIFANLFKGLFGKK) and ARF4 (GLTISSLFS- 
RLFGKK), which are two representative members of the 
ARF family [3]. The amino-terminal region of ARF was cho- 
sen because it has been implicated as an effector domain 
[3,18]. Panels A and B of Fig. 1 show that with 10 ~tM to 
100 ~tM ARF1 (open circles) and ARF4 (closed circles) pep- 
tide, the biogenesis of both CSVs (hsPg, Fig. 1A) and ISGs 
(SglI, Fig. 1B) was progressively inhibited. At 50 ktM and 100 
p.M, the ARF4 peptide was a more potent inhibitor than the 
ARF1 peptide. 
The ARF proteins are N-myristoylated at their amino-term- 
inal glycine residue, a modification shown to be important for 
their membrane association and, hence, their biological activ- 
ity [3]. Membrane association of ARF proteins has also been 
shown to be regulated by their nucleotide state. When in the 
GTP form, they become membrane-associated, an  this mem- 
brane association is greatly enhanced by their N-myristoyla- 
tion [3]. Given the importance of N-myristoylation for the 
membrane association and biological activity of ARF, the 
effects of the synthetic N-myristoylated peptides ARFlmyr 
and ARF4myr, corresponding to the N-terminal 15 residues 
of N-myristoylated ARF1 and ARF4, respectively, were in- 
vestigated. In contrast to the unmodified peptides ARF1 and 
ARF4 (Fig. 1A,B), the N-myristoylated peptides did not in- 
hibit the biogenesis of TGN-derived secretory vesicles (Fig. 
1C,D). Addition of the ARF4myr peptide (closed circles) 
caused a small stimulation of the biogenesis of CSVs (hsPg, 
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Fig. 1C) and ISGs (SglI, Fig. ID). Addition of the ARFlmyr 
peptide (Fig. 1C,D, open circles) resulted in a much greater 
stimulation of the biogenesis of TGN-derived secretory vesi- 
cles, which was 2-fold for CSVs (Fig. 1C) and 2.5-fold for 
ISGs (Fig. 1D) at 100 p.M of the peptide. In conclusion, the 
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data obtained with the unmodified and the N-myristoylated 
peptides indicate a role for ARF proteins, specifically ARF1, 
in the biogenesis of CSVs and ISGs from the TGN. 
3.2. Biogenesis of TGN-derived secretory vesicles in a modified 
cell-free system 
One of the functions of ARF in vesicular transport is 
thought to be in the recruitment of the COP I coat [2,4,5]. 
To investigate whether or not the COP I coat is involved in 
the biogenesis of secretory vesicles from the TGN, we mod- 
ified the previously established cell-free system [9,13], which 
reconstitutes the biogenesis of ISGs and CSVs in a PNS, such 
that TGN membranes could be supplemented with cytosol. 
To establish and characterize the modified cell-free system, 
TGN membranes were prepared from [35S]sulphate-pulse-la- 
belled PC12 cells, supplemented with PC12 cell cytosol to a 
final concentration of 2 mg/ml, and used in cell-free reactions 
with an ATP regenerating or depleting system and 20 p.M 
GTP~S as shown in Fig. 2A,B. At 37°C in the presence of 
an ATP depleting system (37°C -ATP) ,  no significant in- 
crease in the biogenesis of either hsPg- (Fig. 2A) or SgII- 
(Fig. 2B) containing vesicles over the background value ob- 
tained at 4°C in the presence of ATP (4°C +ATP) was ob- 
served. When the temperature was raised to 37°C in the pres- 
ence of an ATP regenerating system, a marked increase in the 
biogenesis of these vesicles was observed (Fig. 2A,B, 37°C 
+ATP). Analysis by equilibrium sucrose gradient centrifuga- 
tion of the hsPg- and SgII-containing vesicles formed in this 
condition showed that, similar to previous observations using 
the PNS-based system [9,16,17], the SglI-containing vesicles 
peaked at higher buoyant density than the hsPg-containing 
vesicles (data not shown), as would be expected for ISGs 
and CSVs, respectively [9]. Therefore the modified cell-free 
system, as is the case for the PNS-based system [9], reconsti- 
tutes the biogenesis of CSVs (hsPg) and ISGs (SgII) from the 
TGN in a temperature and ATP dependent manner. 
Another criterion for the reconstitution of CSV and ISG 
biogenesis in a cell-free system is the inhibition of vesicle 
budding by non-hydrolysable GTP analogues [16,19]. When 
modified cell-free assays were performed in the presence of 20 
~tM GTP~S, the biogenesis of TGN-derived secretory vesicles 
was inhibited (Fig. 2A,B, 37°C +ATP+GTP~/S). These results 
suggest that in the modified cell-free system (see also ref. [20]), 
as in the PNS-based system [16,17,19], the regulation of secre- 
tory vesicle biogenesis by GTP-binding proteins is also recon- 
stituted. 
To further characterise the biogenesis of TGN-derived se- 
cretory vesicles in the modified cell-free system, the require- 
ment for cytosol was investigated. Modified cell-free reactions 
were carried out using TGN membranes supplemented with 
PC12 cell cytosol to the final protein concentrations (between 
0.5 and 5.0 mg/ml) indicated in Fig. 2C. Addition of increas- 
ing concentrations of cytosol resulted in a progressive increase 
in the biogenesis of TGN-derived secretory vesicles, indicating 
that cytosolic omponents were limiting in the cell-free system. 
3.3. Lack of effect of coatomer immunodepletion the cell- 
free biogenesis of TGN-derived secretory vesicles 
The dependence of the biogenesis of TGN-derived secretory 
vesicles on cytosol allowed us to use the modified cell-free 
system to investigate a possible role of coatomer in this proc- 
ess. Rat brain cytosol, which like PC12 cell cytosol supported 
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Fig. 3. Coatomer-depleted cytosol supports the cell-free biogenesis 
of TGN-derived secretory vesicles. Modified cell-free reactions were 
carried out using TGN membranes supplemented with either control 
(Control, GTPyS) or coatomer-depleted (-COP I, -COP I 
+GTPTS) rat brain cytosol to a final protein concentration of 2 mg/ 
ml, in the absence (Control, -COP I) or presence (GTPTS, -COP 
I+GTPyS) of 20 ~M GTPyS. The biogenesis of CSVs (hsPg, A) and 
ISGs (SgII, B) was determined as described in section 2. The bud- 
ding efficiencies are expressed as a percentage of the control, and 
are the means of two independent experiments (Control, -COP I) 
or from a single experiment (GTPTS, -COP I+GTPyS). Bars indi- 
cate the variation of the individual values from the mean. 
the biogenesis of TGN-derived secretory vesicles (data not 
shown), was depleted of coatomer by immunoadsorption. 
The immunodepleted cytosol contained less than 15% of the 
amount of coatomer found in untreated cytosol as determined 
by immunoblotting (data not shown). This level of coatomer 
depletion has been shown by morphological criteria [15] to 
reduce the formation of coated cis-Golgi-derived vesicles by 
80%. We then compared the biogenesis of TGN-derived se- 
cretory vesicles in the modified cell-free system using either 
control or coatomer-depleted cytosol. This comparison should 
reveal a requirement for the COP I coat in the biogenesis of 
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TGN-derived secretory vesicles if coatomer, in analogy to the 
formation of cis-Golgi-derived vesicles [2,15,21], were indeed a 
limiting component in our cell-free system. However, as 
shown in Fig. 3A,B, coatomer-depleted cytosol ( -COP I) 
supported the biogenesis of TGN-derived secretory vesicles 
to the same extent as control cytosol. In either condition, 
the biogenesis of TGN-derived secretory vesicles was sensitive 
to inhibition by GTPTS (Fig. 3A,B, GTP~S, -COP+GTP~S). 
The hsPg- and SglI-containing vesicles formed with coatomer- 
depleted cytosol showed the same differential distribution on 
equilibrium sucrose gradients (indicative of the biogenesis of 
CSVs and ISGs, respectively) as those formed with control 
cytosol (data not shown). 
4. Discussion 
Our results implicate ARF proteins, specifically ARF1, but 
not the COP I coat, in the biogenesis of secretory vesicles 
from the TGN. Our findings are consistent with the observa- 
tion that ARF, but not B-COP, is associated with CSVs of 
hepatocytes [22]. The lack of effect of coatomer depletion in 
the present modified cell-free system is in agreement with the 
lack of stimulation of secretory vesicle biogenesis by a coat- 
omer-enriched cytosol fraction in a similar cytosol-dependent 
cell-free system [23]. Our observations are also in line with the 
results of a previous tudy addressing the role of coatomer in 
vivo, which shows that ~-COP antibodies block membrane 
transport from the endoplasmic reticulum to the Golgi com- 
plex but not from the TGN to the plasma membrane [24]. 
Hence, it appears that the biogenesis of TGN-derived secre- 
tory vesicles is a COP I-independent process. Perhaps the 
biogenesis of TGN-derived secretory vesicles involves coats 
other than COP I, such as the 'lace-like' coat in the case of 
CSVs [25], or no coat, as has been discussed for ISGs [26]. 
The extent of stimulation and inhibition of TGN-derived 
secretory vesicle biogenesis by the N-myristoylated and the 
non-myristoylated ARF peptides, respectively, was different 
for ARF1 and ARF4. The N-myristoylated ARF1 peptide 
was a much more potent stimulator than the N-myristoylated 
ARF4 peptide, whereas the non-myristoylated ARF4 peptide 
was slightly more inhibitory than the non-myristoylated 
ARF1 peptide. This may reflect differences in the mechanisms 
underlying the stimulatory and inhibitory effects of the ARF 
peptides. The inhibitory effect of the non-myristoylated ARF1 
and ARF4 peptides on the biogenesis of TGN-derived secre- 
tory vesicles may be interpreted in the same way as the in- 
hibition by such peptides of vesicle formation from more 
proximal compartments of the secretory pathway [27,28], i.e. 
as a competitive action on endogenous ARF (presumably 
ARF1). If so, our data would imply that both the non-myr- 
istoylated ARF1 and ARF4 peptides can act as such compe- 
titive inhibitors [27]. However, the ability of the N-myristoy- 
lated ARF peptides, especially the ARF1 peptide, to stimulate 
secretory vesicle formation is remarkable, in particular if the 
only role of ARF in the biogenesis of TGN-derived secretory 
vesicles were the recruitment of, as yet poorly characterized, 
coat proteins. In this case, one would have to assume that this 
peptide, which is only 15 amino acid residues long, suffices to 
mediate the recruitment of these coat proteins to the TGN 
membrane. An alternative interpretation, which we favour, is 
that the stimulation of biogenesis of TGN-derived secretory 
vesicles by the N-myristoylated ARF1 peptide reflected the 
activation of phospholipase D. Phospholipase D appears to 
be present on Golgi membranes [29], is stimulated by ARF via 
ARF's myristoylated amino-terminal domain [30-32], and this 
stimulation is inhibited by brefeldin A [29]. Perhaps the N- 
myristoylated ARF1 peptide was more potent in eliciting a 
phospholipase D activation relevant o TGN-derived secre- 
tory vesicle biogenesis than the N-myristoylated ARF4 pep- 
tide [33]. A role of phospholipase D in the biogenesis of TGN- 
derived secretory vesicles would be consistent with the grow- 
ing evidence implicating lipid modifications in the course of 
vesicle budding and fission [23,34-37]. 
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